Comprehensive Geriatric Assessment May Predict Survival Based on Frailty in Hematologic Malignancies
June 2nd 2022Investigators indicated that comprehensive geriatric assessment could be used to determine whether older, frail patients with hematologic cancers can undergo intensive treatment with chemotherapy and whether curative treatment is viable.
Alina Markova, MD, on the Rationale for Assessing Topical Ruxolitinib in Cutaneous Chronic GVHD
May 13th 2022Alina Markova, MD, discusses the rationale for assessing topical ruxolitinib INCB018424 phosphate 1.5% cream in patients with non-sclerotic and superficially sclerotic chronic cutaneous graft-versus-host disease.
Dearth of Participation From Black Patients Noted in CAR T Clinical Trials Supporting FDA Approvals
May 9th 2022Investigators identified that in pivotal clinical trials supporting FDA approvals of CAR T-cell therapies for patients with hematologic cancer, Black patients were significantly underrepresented.
Clinical Scenario 1: First- and Second-Line Treatment for GVHD
April 28th 2022John F. DiPersio, MD, PhD, presents the clinical scenario of a 71-year-old patient postmatched unrelated donor HSCT, and the panel discusses first- and second-line treatment approaches including topical and systemic therapies.